US Stock MarketDetailed Quotes

NVO Novo-Nordisk A/S

Watchlist

85.000
-18.440-17.83%

Close Dec 20 16:00 ET

86.090
+1.090+1.28%

Post 20:01 ET

378.77BMarket Cap28.86P/E (TTM)

Novo-Nordisk A/S Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Novo-Nordisk A/S Q3 2024 Earnings Date

Currency：DKKNov 6, 2024

	Estimate (YoY)	Actual (YoY)	Vs Estimate (% Chg)
Revenue	71.87B	71.31B	-558.36M
Miss Est.	+22.37%	+21.42%	-0.78%
EPS	5.95	6.12	+0.17
Beat Est.	+19.03%	+22.40%	+2.83%

Analyst Rating

Buy

Dec 20, 2024

Novo-Nordisk A/S Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: DKK

Actual

Estimate

Date	Period	Revenue/Estimate	Earnings Call
--	2025/Q1	-- / 79.538B	--
--	2024/Q4	-- / 81.107B	--
Nov 6, 2024	2024/Q3	71.311B / 71.869B	--
Aug 7, 2024	2024/Q2	68.060B / 68.563B	--
May 2, 2024	2024/Q1	65.349B / 63.573B	--

DatePeriodRevenue/EstimateEarnings Call

--2025/Q1-- / 79.538B--

--2024/Q4-- / 81.107B--

Nov 6, 20242024/Q371.311B / 71.869B--

Aug 7, 20242024/Q268.060B / 68.563B--

May 2, 20242024/Q165.349B / 63.573B--

Unlock Free Earnings Estimates

Open Account

Novo-Nordisk A/S Earnings Reports

6-K: Financial Report for the Period 1 January 2024 to 30 September 2024

Nov 6 06:37 ET

6-K: Financial Report for the Period 1 January 2024 to 30 June 2024

Aug 7 06:56 ET

6-K: Novo Nordisk Stops the Ocedurenone CLARION-CKD Trial and Recognises Impairment Loss

Jun 26 13:22 ET

6-K: Financial Report for the Period 1 January 2024 to 31 March 2024

May 2 07:18 ET

Trending US Stocks

Symbol Mini Chart % Chg

Unlock the Full List

Analysis

Analyst Rating

Updated: Dec 20, 2024

Buy

Buy
57.14%
Hold
28.57%
Sell
14.29%

Price Target

No Data

Investment Theme

Weight Loss Drugs

Intraday-4.61%